SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-068591
Filing Date
2023-12-06
Accepted
2023-12-06 17:08:19
Documents
12
Period of Report
2023-12-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20231204.htm   iXBRL 8-K 35162
  Complete submission text file 0000950170-23-068591.txt   150481

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20231204.xsd EX-101.SCH 2463
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20231204_lab.xml EX-101.LAB 13352
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20231204_pre.xml EX-101.PRE 9839
6 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20231204_htm.xml XML 4705
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 231470434
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences